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Infectious Disorders
Cefpirome as empirical treatment for febrile
neutropenia in patients with hematologic
malignancies
Cefpirome, a fourth generation cephalosporin,
was administered during 154 episodes of febrile
neutropenia in 106 patients. We assessed the clin-
ical efficacy of cefpirome and its activity against
isolated pathogens in neutropenic patients with
hematologic malignancies. In addition, the phar-
macokinetics and optimal dosing regimen of cef-
pirome during neutropenia were investigated.
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Cefpirome is a fourth generation cephalosporin, with a
broad spectrum of antibacterial activity. As compared
with third generation cephalosporins the drug has better
activity against Gram-positive micro-organisms and
greater stability to beta-lactamases. Moreover, cefpirome
is generally well tolerated. In view of these properties
cefpirome may be suitable for the empirical treatment of
fever in neutropenic patients. Open trials, as well as some
randomized studies, have shown promising results.1-3
The dosage of cefpirome recommended by the manu-
facturer for infections in neutropenic patients is 2 g twice
daily. However, though pharmacokinetics have been
investigated in healthy volunteers, data during neutrope-
nia are lacking. 
We performed an open label, non-randomized clinical
study to assess the clinical efficacy of cefpirome and its
activity against isolated pathogens in neutropenic
patients with hematologic malignancies. In addition, the
pharmacokinetics and optimal dosing regimen of cef-
pirome in this population were investigated.
During a two-year study period cefpirome was admin-
istered during 154 neutropenic episodes in 106 patients.
The dose given was 2g twice daily, intravenously.
Patients were eligible if they were admitted to the hema-
tology ward of our hospital for chemotherapeutic treat-
ment of hematologic malignancies and became febrile
(T>38.5°C) during the neutropenic episode (neutropenia
defined as an absolute neutrophil count (ANC)
<0.5¥109/L). For prevention purposes all patients had ini-
tially received systemic antimicrobial prophylaxis, com-
prising oral ciprofloxacin, azithromycin, fluconazole and
nasal amphotericin B. The patients’ characteristics, dis-
ease and treatment variables are given in Table 1.
Patients were evaluated for causes of fever and clinical
outcome. A microbiologically documented infection
(MDI) was evidenced in 55 (36%) of episodes, a clinical-
ly documented infection (CDI) in 40 (26%) and fever of
unknown origin (FUO) in 59 (38%) (Table 2). Cefpirome
treatment was considered to have been successful if the
patient survived the episode of fever and neutropenia
without any modification of the cefpirome regimen, and
without signs of remaining active infection.4 Treatment
was successful in 81 (53%) of the 154 episodes. The rate
of success was highest in the episodes of FUO (45/59;
76%), less in the episodes of CD1 (21/40; 53%) and low-
est in the episodes of MDI (15/55; 27%). The toxicity
profile of cefpirome appeared to be favorable. Skin rash,
possibly caused by cefpirome, occurred in 14 episodes.
No other toxicities of the study treatment were observed.
Seven patients died during the study period. Four were
still febrile (MDI n=3, CDI n=1), three others died of dis-
ease progression (n=2) or cerebral hemorrhage (n=1).
Susceptibility patterns of isolated pathogens were
determined by standard microbiological techniques,
which classified strains as sensitive (S), intermediate sus-
ceptible (I) or resistant (R), and are given in Table 2. The
majority of the Gram-positive cocci and Gram-negative
rods isolated were susceptible to cefpirome. However, all
isolates of enterococci (E. faecium and E. faecalis),
Corynebacterium jeikeijum and Stenotrophomonas maltophilia
were resistant. Pseudomonas aeruginosae were susceptible
to cefpirome in vitro. However, MIC90 values between
12.5 and >32 mg/L have been reported, indicating bor-
derline susceptibility or resistance.5,6
Cefpirome serum levels were measured in a subgroup
of 24 patients, randomly selected from the total of 106
patients entered in the study. On the final day of cef-
pirome treatment the standard dosing regimen was
switched to one of three different dosing regimens.
Group I (n=8) continued to receive cefpirome 2 g twice
daily, group II (n=8) received cefpirome 1 g three times
daily and group III (n=8) received a single dose of 500 mg
followed by 3 g cefpirome continuously i.v. A two-com-
partment model was constructed to predict the duration
of time between cefpirome administration and the
moment that the serum concentration dropped below 4
mg/L, for each of the different dosing regimens. The con-
centration of 4 mg/L was defined as a target concentra-
tion to be exceeded, being the MIC50 and a breakpoint for
Pseudomonas aeruginosa.7 Group I patients had serum con-
centrations >4 mg/L for a mean of 87.5% of the time,
group II for 92.6% of the time (p=0.4) and group III for
100% of the time (p=0.01). Cefpirome 2 g twice daily is
recommended by the manufacturer as a dosing regimen 
Table 1. Characteristics of the patients and infections episodes.
Characteristics Number of episodes (%)
Unless otherwise specified
General characteristics
Number of neutropenic episodes 154
Number of patients 106
Male/ female 63/ 43 (59/ 41)
Age (years, mean ± SD) 50.2±13.6
Diagnoses (in 106 patients) 
Acute myeloid leukemia 44 (41)
Acute lymphoblastic leukemia 8 (7)
Myelodysplastic syndrome 6 (6)
Lymphoma 21 (20)
Multiple myeloma 20 (19)
Chronic myeloid leukemia 6 (6)
Hairy cell leukemia 1 (1)
Treatment  (in 154 neutropenic episodes)
Autologous stem cell transplantation 58 (38)
Central venous access catheter 148 (96)
Neutropenic episode# (days, mean ± SD) 24.8±9.5
Duration of fever (days, mean ± SD) 4.5±4
Duration of fever (days, range) 1-25
Cefpirome 
Treatment days (mean ± SD) 9.8±6.2
Treatment days (range) 1-42
#Duration of the neutropenia is calculated from the start of chemotherapy until 
absolute neutrophil count (ANC) >0.5¥109/L.
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for infections in neutropenic patients and our data con-
firm that this may be adequate.  
In view of the available efficacy data, its broad antibac-
terial coverage and favorable toxicity profile, cefpirome,
at the recommended dose of 2 g twice daily, appears to
be a valuable addition to the therapeutic arsenal available
for febrile neutropenia. However, limited activity against
Pseudomonas spp. may in the long run hamper its use as
single agent therapy
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Table 2. Pathogens isolated and their susceptibility patterns.
Causes of fever No. of No. of strains sensitive (S),
episodes intermediate (I) 
or resistant (R)   
to cefpirome
S I R
Microbiologically 55 
documented infections (36%)
Bloodstream infections 40
Coagulase negative 10 10
staphylococci
Viridans group (VG) 16 15 1
streptococci
Enterococci 7 7
Corynebacterium jeikeijum 3 3
Pseudomonas aeruginosa 2 2
Candida tropicalis 1
Other 1 1
Respiratory tract infections 10
Pseudomonas aeruginosa 3 3
Stenotrophomonas maltophilia 2 1 1
Serratia marcescens 2 2
E. coli 1 1
Aspergillus fumigatus 2
Urinary tract infections 3
Enterococci 2 2
Proteus mirabilis 1 1
Other 2 1 1
Clinically documented 40 (26%)
infections
Lungs 14
Ear, nose, throat 8
Sinuses 10
Skin 3
Genital or (peri) anal 4
Other 1
Fever of unknown origin (FUO) 59
(38%)
